Abstract
Purpose This paper describes the clinical features, genotype phenotype correlation of CERKL gene mutation, one of the most common genetic mutations of Inherited Retinal Dystrophy (IRD) patients seen in our cohort in North India.
Materials and Methods Patients clinically diagnosed with an IRD were included in the study. Patients underwent ultra widefield (UWF) fundus photographs, fundus autofluorescence (FAF), optical coherence tomography (OCT). A pedigree charting was done. Genetic testing by next generation sequencing (NGS) was done, clinical exome was analyzed.
Results We report ophthalmic and genetic findings of seven patients with CERKL gene mutation of the thirty five patients that chose to undergo genetic sequencing (amongst our cohort of sixty two patients with IRD). The age ranged from 17 to 45 (median 25) years. Vision ranged from LogMAR 0.18 to 1.8. OCT showed central macular thickness (CMT) ranging from 103 to 268 microns. Majority patients’ fundus exhibited macular pigmentary changes with atrophy, paucipigmentary or limited peripheral retinal pigmentary changes; mild optic disc pallor, and minimal vascular attenuation. Stippled hypo autofluorescence at the macula was the most common finding, with minimal hypoautoflorescence in the retinal periphery.. The genetic sequencing of all patients showed the same mutation, a 2 base pair deletion in exon 7 of the CERKL gene (chr2:g.181548785_181548786del). Coincidentally, all patients with CERKL gene mutation were found to be from a single ethnic community suggesting a founder mutation effect.
Conclusions Mutation in the CERKL gene results are among the most common causes of IRD in North India. Affected patients showed a definitive early macular involvement. This study reports the presence of a founder mutation effect in the CERKL gene in a large ethnic community in North India.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institute Ethics Committee, Fortis Memorial Research Institute, Gurugram, India
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors